Retrospect and outlook

As mentioned in the 2021 Remuneration report, DSM intended to revise its Remuneration policy in 2022. In view of the intended merger with Firmenich and consequently the change of the regulatory environment, this project was interrupted. Following a successful completion of the intended merger with Firmenich, the DSM-Firmenich shareholders will at each annual General Meeting have the opportunity to vote, with non-binding effect, on DSM-Firmenich’s remuneration report (for the prior financial year) and, with binding effect, on the maximum remuneration envelope for the members of the Board of Directors of DSM-Firmenich (until the next annual General Meeting) and the Executive Committee of DSM-Firmenich (for the next financial year).